Jim Xiang

2.7k total citations
61 papers, 1.9k citations indexed

About

Jim Xiang is a scholar working on Pharmacology, Physiology and Surgery. According to data from OpenAlex, Jim Xiang has authored 61 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pharmacology, 22 papers in Physiology and 11 papers in Surgery. Recurrent topics in Jim Xiang's work include Pain Mechanisms and Treatments (19 papers), Musculoskeletal pain and rehabilitation (10 papers) and Pneumonia and Respiratory Infections (10 papers). Jim Xiang is often cited by papers focused on Pain Mechanisms and Treatments (19 papers), Musculoskeletal pain and rehabilitation (10 papers) and Pneumonia and Respiratory Infections (10 papers). Jim Xiang collaborates with scholars based in United States, Belgium and Italy. Jim Xiang's co-authors include Norman Rosenthal, Donna Jordan, James B. Kahn, G. Vorsanger, Alan M. Tennenberg, Mohammed M. Khashab, Neringa Zadeikis, David Hewitt, Philip Raskin and Lala M. Dunbar and has published in prestigious journals such as Gastroenterology, Neurology and Clinical Infectious Diseases.

In The Last Decade

Jim Xiang

60 papers receiving 1.8k citations

Peers

Countries citing papers authored by Jim Xiang

Since Specialization

Citations

This map shows the geographic impact of Jim Xiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Xiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Xiang more than expected).

Fields of papers citing papers by Jim Xiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim Xiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Xiang. The network helps show where Jim Xiang may publish in the future.

Co-authorship network of co-authors of Jim Xiang

This figure shows the co-authorship network connecting the top 25 collaborators of Jim Xiang. A scholar is included among the top collaborators of Jim Xiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim Xiang. Jim Xiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expansion of moments of Bernstein polynomials 2019 ·Journal of Mathematical Analysis and Applications ·Jim Xiang	3
2	Extended-release tramadol (tramadol ER) in the treatment of chronic low back pain 2018 ·Journal of Opioid Management ·G. Vorsanger, Jim Xiang, Theophilus J. Gana, (unknown), (unknown)	20
3	70 Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism from the Emergency Department 2017 ·Annals of Emergency Medicine ·W. Frank Peacock, (unknown), (unknown), Christopher Kabrhel, C. A. Keay, (unknown), (unknown), Peter Wildgoose, Jim Xiang, A. Singer	2
4	Development and preliminary validation of an integrated efficacy–tolerability composite measure for the evaluation of analgesics 2015 ·Pain ·Nathaniel P. Katz, (unknown), Jeremiah Trudeau, Jim Xiang, G. Vorsanger, Camille Orman, Myoung Kim	5
5	Tolerability and efficacy of tapentadol extended release in elderly patients ≥75 years of age with chronic osteoarthritis knee or low back pain 2015 ·Journal of Opioid Management ·David M. Biondi, Jim Xiang, Mila Etropolski, Bruce L. Moskovitz	27
6	Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation 2014 ·Journal of Interventional Cardiac Electrophysiology ·(unknown), Gerald V. Naccarelli, Riccardo Cappato, Stefan H. Hohnloser, Francis E. Marchlinski, David J. Wilber, Jim Xiang, Changsheng Ma, Susanne Hess, David Wyn Davies, Larry E. Fields, Andrea Natale	13
7	Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: A randomized, phase IIIb study 2013 ·Journal of Opioid Management ·G. Vorsanger, (unknown), Jim Xiang, Carmela Benson, Bruce L. Moskovitz, Norman Rosenthal	17
8	Evaluation of study discontinuations with tapentadol immediate release and oxycodone immediate release in patients with low back or osteoarthritis pain 2011 ·Journal of Opioid Management ·G. Vorsanger, Jim Xiang, (unknown), David Upmalis, Bruce L. Moskovitz	19
9	Tramadol Hydrochloride Extended-Release Once-Daily in the Treatment of Osteoarthritis of the Knee and/or Hip: A Double-Blind, Randomized, Dose-Ranging Trial 2010 ·American Journal of Therapeutics ·(unknown), Jim Xiang, Carmela Benson, Theophilus J. Gana, (unknown), (unknown), Braden C. Fleming	57
10	Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs 2009 ·Clinical Therapeutics ·David W. Dodick, Fred Freitag, James Banks, Joel R. Saper, Jim Xiang, Marcia F.T. Rupnow, David M. Biondi, Steven J. Greenberg, Joseph Hulihan	103
11	Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Efficacy and Tolerability Study of Tramadol Extended Release for the Treatment of Osteoarthritis Pain in Geriatric Patients 2007 ·Clinical Therapeutics ·G. Vorsanger, Jim Xiang, Donna Jordan, (unknown)	30
12	(745) 2007 ·Journal of Pain ·Jim Xiang, C Janagap, Donna Jordan, G. Vorsanger	3
13	Extended-release tramadol in the treatment of osteoarthritis:a multicenter, randomized, double-blind, placebo-controlled clinical trial 2006 ·Current Medical Research and Opinion ·Theophilus J. Gana, (unknown), (unknown), Jeff Schein, C Janagap, Jim Xiang, G. Vorsanger, (unknown)	96
14	Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients 2006 ·Respiratory Medicine ·Andrew F. Shorr, Mohammed M. Khashab, Jim Xiang, Alan M. Tennenberg, James B. Kahn	32
15	Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections 2006 ·Current Medical Research and Opinion ·Mohammed M. Khashab, Jim Xiang, James B. Kahn	17
16	Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis 2006 ·Diagnostic Microbiology and Infectious Disease ·Jack B. Anon, (unknown), Jim Xiang, Paul G. Ambrose, Ronald N. Jones, James B. Kahn	11
17	Adjunctive Topiramate Therapy in Patients Receiving a Mood Stabilizer for Bipolar I Disorder 2006 ·The Journal of Clinical Psychiatry ·K. N. Roy Chengappa, (unknown), Joseph Hulihan, Jim Xiang, Norman Rosenthal	46
18	Tramadol/acetaminophen tablets in the treatment of postsurgical orthopedic pain. 2005 ·PubMed ·Michael H. Bourne, Norman Rosenthal, Jim Xiang, Donna Jordan, Marc Kamin	24
19	Combination tramadol plus acetaminophen for postsurgical pain 2004 ·The American Journal of Surgery ·Adam B. Smith, Thanjavur S. Ravikumar, Marc Kamin, Donna Jordan, Jim Xiang, Norman Rosenthal	52
20	A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol 2002 ·Clinical Therapeutics ·Gail Shapiro, (unknown), Jim Xiang, John Kottakis, Giovanni Della Cioppa	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact